Peptidase Industry 2024: Market Trends, Brand Comparisons, and Technical Advantages
Abstract: The 2024 peptidase industry is driven by expanding applications in therapeutics, nutraceuticals, and cosmetics. Market data indicates a 7.8% CAGR, with serine and metallopeptidases dominating due to superior stability and specificity. Brand comparisons reveal Novozymes leading in enzymatic efficiency (≥95% purity), while DSM excels in cold-adapted variants. Technical advantages include enhanced bioavailability and targeted cleavage, though limitations persist in pH sensitivity and production costs. Product certifications (GMP, ISO 22000) and factory audits remain critical for quality assurance. Logistics require strict cold-chain compliance (2–8°C) to maintain activity. Selection criteria prioritize substrate specificity, regulatory approvals, and batch consistency.